空中救护车运送并给予四因子凝血酶原复合物可行且缩短抗凝逆转时间
该回顾性病历回顾纳入2014年4月1日至2016年6月30日期间在大型学术医学中心急诊科接受四因子凝血酶原复合物治疗、且INR>1.5正在接受华法林治疗的转运患者72例。干预组由空中救护车在转运前或转运中给予四因子凝血酶原复合物,常规组在经空中或地面转运后接受四因子凝血酶原复合物或未接受该治疗。干预组到达急诊时INR≤1.5的比例更高(比例差=0.82,95%CI 0.64-0.92,p<0.0001),观察到INR≤1.5的时间显著缩短(181分钟 vs 541分钟,p=0.001)。两组血栓栓塞并发症或患者中心结局无差异,但干预组死亡率显著更高,且该组转运前GCS评分更低、插管率更高。
要点
- 华法林相关大出血、INR>1.5的转运患者,空中救护车在转运前或转运中给予四因子凝血酶原复合物后,到达急诊时INR≤1.5的比例差为0.82(95%CI 0.64-0.92,p<0.0001)。
- 干预组观察到INR≤1.5的时间为181分钟,常规组为541分钟,干预组显著缩短(p=0.001)。
- 两组血栓栓塞并发症无差异,但干预组死亡率显著更高;干预组转运前GCS评分更低、插管率更高。
- 该研究为回顾性病历回顾,共纳入72例患者,作者结论为空中救护车携带四因子凝血酶原复合物并在转运前给予是可行的,且可使华法林相关大出血患者INR更快改善。
适用人群与场景
- 2014年4月1日至2016年6月30日期间就诊于大型学术医学中心急诊科、接受四因子凝血酶原复合物治疗的患者。
- 仅纳入正在接受华法林治疗且INR>1.5的转运患者。
诊断标准与关键阈值
- 纳入标准:正在接受华法林治疗且INR>1.5的转运患者。
- 主要结局指标:到达三级医院时INR≤1.5的患者比例。
处置流程与药物剂量
- 干预组:由空中救护车在转运前或转运中给予四因子凝血酶原复合物。
- 常规组:经空中或地面转运后接受四因子凝血酶原复合物,或未接受四因子凝血酶原复合物治疗。
研究设计与关键结果
- 研究类型:回顾性病历回顾,单中心(大型学术医学中心),共纳入72例患者。
- 主要终点:干预组到达急诊时INR≤1.5的比例更高,比例差=0.82(95%CI 0.64-0.92,p<0.0001)。
- 次要疗效终点:干预组观察到INR≤1.5的时间为181分钟,常规组为541分钟,干预组显著缩短(p=0.001)。
- 安全性终点:两组血栓栓塞并发症无差异。
- 其他结局:两组患者中心结局无差异,但干预组死亡率显著更高;干预组转运前GCS评分更低、插管率更高。
证据类型、等级与局限
- 证据类型:回顾性病历回顾。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论:空中救护车携带四因子凝血酶原复合物并在转运前给予是可行的,且可使华法林相关大出血患者INR更快改善。
- 干预组死亡率显著更高,且该组转运前GCS评分更低、插管率更高,解读死亡结局时需考虑组间基线差异。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: The objective was to evaluate the feasibility, safety, and preliminary efficacy of four-factor prothrombin complex concentrate (4-factor PCC) administration by an air ambulance service prior to or during transfer of patients with warfarin-associated major hemorrhage to a tertiary care center for definitive management (interventional arm) compared to patients receiving 4-factor PCC following transfer by air ambulance or ground without 4-factor PCC treatment (conventional arm).
METHODS: This was a retrospective chart review of patients presenting to a large academic medical center. All patients presenting to the emergency department (ED) treated with 4-factor PCC from April 1, 2014, through June 30, 2016, were identified. For this study, only transfer patients with an International Normalized Ratio (INR) > 1.5 actively treated with warfarin were included. The primary outcome was the proportion of patients with an INR ≤ 1.5 upon tertiary care hospital arrival, and the secondary efficacy outcome was difference in time to achievement of INR ≤ 1.5. Additional safety and efficacy objectives included difference in thromboembolic complications, length of stay, intensive care unit length of stay, and inpatient mortality between groups.
RESULTS: Of the 72 included patients, a higher proportion of patients in the interventional group had an INR ≤ 1.5 on ED arrival (proportion difference = 0.82, 95% confidence interval = 0.64-0.92, p < 0.0001) and significantly reduced time to observed INR ≤ 1.5 (181 minutes vs. 541 minutes, p = 0.001). No differences were observed in thromboembolic complications or patient-centered outcomes with the exception of mortality, which was significantly higher in patients in the interventional group. This group was also observed to have lower Glasgow Coma Scale score and higher intubation rates prior to transfer and treatment.
CONCLUSIONS: Dispatch of an air ambulance carrying 4-factor PCC with administration prior to transfer is feasible and leads to more rapid improvement in INR among patients with warfarin-associated major hemorrhage.
参考来源
- Vines C, Tesseneer SJ, Cox RD, et al. Air Ambulance Delivery and Administration of Four-factor Prothrombin Complex Concentrate Is Feasible and Decreases Time to Anticoagulation Reversal. Acad Emerg Med. 2017. PMID: 29077228. doi:10.1111/acem.13338
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。